At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

The bear phase in Regeneron (REGN) appears over. Shares bottomed at around $550 - $575 and jumped by around 12% to over $650 ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...

Regeneron Pharmaceuticals (($REGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Regeneron Pharmaceuticals’ recent ...

Across its portfolio, Regeneron brought in $3.75 billion in sales and adjusted earnings of $11.83 a share. Sales edged 1% ...

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.